Advertisement

Topics

Latest "Biogen Incorporated" News Stories

19:50 EST 18th November 2018 | BioPortfolio

Here are the most relevant search results for "Biogen Incorporated" found in our extensive news archives from over 250 global news sources.

More Information about Biogen Incorporated on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biogen Incorporated for you to read. Along with our medical data and news we also list Biogen Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biogen Incorporated Companies for you to search.

Showing "Biogen Incorporated" News Articles 1–25 of 598

Sunday 18th November 2018

Biogen Scoops Sixth Prix Galien Award with UK Win for Life-Changing Rare Disease Medicine

Spinraza® (nusinersen) yet to be made available by NHS England following NICE interim rejection


Friday 16th November 2018

Orphan drugs from Biogen and Amicus win UK Prix Galien

New medical technology category added for the first time

Thursday 15th November 2018

Superior Controls - First Company Globally to Achieve CSIA Certification for the Seventh Consecutive Time

Superior Controls is part of an elite group of system integrators achieving the highest level of certification in the Control System Integrator Association’s Certification program and the first to pass its seventh consecutive certification audit as required every three years. SEABROOK, N.H. (PRWEB) November 15, 2018 Superior Controls, Inc., a leading 25-year-old control system integrator of cus...


Wednesday 14th November 2018

HemaCare Provides Starting Material for Three FDA Approved Cellular Therapies

40-Years of Blood Collection and Processing Proudly Supporting the Development of Life-Changing Medicines HemaCare Corporation (OTCMKTS: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announces their involvement as a provider of

Millendo Therapeutics Strengthens Executive Team with Key Appointments

Louis Arcudi III appointed as Chief Financial Officer Michael Yeh appointed as Vice President of Medical Affairs Millendo Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for orphan endocrine diseases, today announced the appointments of Louis Arcudi III as Chief Financial Officer and Micha...

Tuesday 13th November 2018

Biogen: Spinning Around Spinraza

Sigilon Therapeutics Announces Appointment of Four New Members of Senior Management Team

Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics, today announced the appointment of four new members of its senior management team as the company prepares to advance its lead therapeutic candidate into clinical trials. Deya Corzo, M.D., FACMG, joins the company as Chief Med...

Akili Builds Medical Team with Newly Appointed Medical Affairs Leader and Formation of Clinical Advisory Committee in Preparation for Commercial Launch

Anil S. Jina, M.D., Joins Akili to Build and Lead Medical Affairs Team Leading Clinicians and Researchers Will Advise on the Expansion of Akili’s Lead Investigational Product and Pipeline of Digital Medicine Products Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing no...

Sunday 11th November 2018

BioDuro LLC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

Summary 2015 - BioDuro is reacquired from PPD. BioDuro and Formex merge to enable service offerings that span from API synthesis to formulation development and cGMP manufacture of drug product. BioDuro LLC BioDuro, a subsidiary of Pharmaceutical Product Development LLC is a discoverer and developer of small molecule and biologics. The institute offers discovery, development and manufacturing...

Friday 9th November 2018

Biogen's aducanumab shows continued improvements through 48 weeks in Phase Ib extension for Alzheimer’s

Thursday 8th November 2018

Superior Controls to Exhibit at Rockwell Automation Solution Partner and Life Sciences Manufacturing Automation Fair® in Philadelphia

Recognized as one of the world’s leading independent engineering firms implementing validated automation systems for the Biotech and Life Science industries, Superior Controls will exhibit November 14-15 at the 2018 Automation Fair® presented by Rockwell Automation. SEABROOK, N.H. and PHILADELPHIA (PRWEB) November 08, 2018 Superior Controls, Inc., a leading 25-year-old control system integ...

Ligand Reports Third Quarter 2018 Financial Results

Raises 2018 Financial Guidance Conference Call Begins at 9:00 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call today b...

Wednesday 7th November 2018

Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products Heidelberg, Germany and Cambridge, UK, 07 November 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced a supply and license agreement with United States based Life Sciences company, Quanterix Corporation. The agreement provi...

Tuesday 6th November 2018

Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million

Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.

Mannatech Reports Third Quarter 2018 Financial Results

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2018. Third Quarter Results Third quarter net

Alzheimer's Pathways: An Investor's Guide To Biogen, Anavex, And Neurotrope

Samsung BioLogics, Biogen Conclude Asset Transfer

Transfers shares of Samsung Bioepis for $677 million

Friday 2nd November 2018

Adalimumab biosimilars Amgevita and Imraldi launched in Europe

In October 2018, two adalimumab biosimilars have been launched in the European Union (EU). Amgen announced the European launch of its adalimumab biosimilar, Amgevita and Biogen announced the launch of its adalimumab biosimilar Imraldi.

Thursday 1st November 2018

Probiodrug (PBD) - Support for Abeta theory from Biogen/Eisai

Edison Investment Research - Pharmaceutical & healthcare - Probiodrug: We believe one of the main reasons for the devaluation of Probiodrug’s shares over the past year was the largely disappointing industry newsflow frustrating research on Abeta theory, even though Probiodrug’s technology is differentiated from all other Abeta therapies studied in late-stage trials. The recent surprise...

Teleflex Reports Third Quarter 2018 Results

Third Quarter Revenues of $609.7 million, up 14.0% Versus Prior Year Period; up 15.0% on Constant Currency Basis Third Quarter GAAP Diluted EPS of $1.21, down 28.8% Over the Prior Year Period Third Quarter Adjusted Diluted EPS of $2.52, up 18.9% Versus Prior Year Period Lowered 2018 Guidance Range for GAAP Revenue Growth f...

Wednesday 31st October 2018

Forward Pharma Loses Patent Appeal Against Biogen

A US federal appeals court has rejected an appeal by Danish biopharma Forward Pharma against the validity of Biogen’s patent for blockbuster multiple sclerosis (MS) drug Tecfidera. The ruling frees Biogen from having to pay future royalty payments to Forward Pharma for the drug and secures the US biotech’s exclusivity on Tecfidera until 2028. Tecfidera had sales of around $4.2 billion ...

Tuesday 30th October 2018

Vernalis Plc VER Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryVernalis plc Vernalis is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a onceaday formulation of the antibiotic amoxicillin, indicated for the treat...

Biogen-Aktie: Outperformance erwartet!

New York (www.aktiencheck.de) - Biogen-Aktienanalyse von Analyst Jay Olson von Oppenheimer: Laut einer Aktienanalyse äußert Analyst Jay Olson vom Investmenthaus Oppenheimer weiterhin die Erwartung ...

Monday 29th October 2018

Biogen: One More Time Around The Alzheimer's Block

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks